Bosh sahifa4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Yopilish kursi
2 244,00 ¥
Kunlik diapazon
2 247,00 ¥ - 2 274,00 ¥
Yillik diapazon
1 921,00 ¥ - 2 411,00 ¥
Bozor kapitalizatsiyasi
119,94 mlrd JPY
Oʻrtacha hajm
63,62 ming
Narx/foyda
11,86
Dividend daromadliligi
1,99%
Asosiy maydon
TYO
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(JPY) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 20,97 mlrd | 14,11% |
Joriy xarajat | 12,52 mlrd | 14,20% |
Sof foyda | 1,85 mlrd | -25,47% |
Sof foyda marjasi | 8,82 | -34,67% |
Har bir ulushga tushum | — | — |
EBITDA | 4,39 mlrd | 8,29% |
Amaldagi soliq stavkasi | 17,59% | — |
Balans
Jami aktivlari
Jami passivlari
(JPY) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 24,36 mlrd | 31,90% |
Jami aktivlari | 158,34 mlrd | 6,87% |
Jami passivlari | 69,77 mlrd | -3,36% |
Umumiy kapital | 88,57 mlrd | — |
Tarqatilgan aksiyalar | 44,08 mln | — |
Narxi/balansdagi bahosi | 1,12 | — |
Aktivlardan daromad | 4,06% | — |
Kapitaldan daromad | 4,89% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(JPY) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | 1,85 mlrd | -25,47% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
CEO
Tashkil etilgan
22-dek, 1955
Sayt
Xodimlar soni
1 777